Sundry Photography/iStock Editorial via Getty Images
Merck (NYSE:MRK) said the FDA has approved its drug Welireg for the treatment of advanced kidney cancer.
The product, also known as belzutifan, was approved for patients with advanced renal cell carcinoma following PD-1 or PD-1 inhibitor and a VEGF-TKI therapy. Welireg belongs to a newer class of therapeutics known as hypoxia-inducible factor-2 alpha inhibitors.
More on Merck
- Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
- Merck Will Keep Your Retirement Income Healthy
- Merck: Not The Time To Be Adding
- Moderna, Merck post three-year data for mRNA-based skin cancer therapy
- C4 Therapeutics stock rallies on Merck deal to develop cancer antibodies